Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.

Ferrer-Font L, Arias-Ramos N, Lope-Piedrafita S, Julià-Sapé M, Pumarola M, Arús C, Candiota AP.

NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3748. Epub 2017 Jun 1.

PMID:
28570014
2.

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, Mocioiu V, Julià-Sapé M, Pumarola M, Arús C, Candiota AP.

Metabolites. 2017 May 18;7(2). pii: E20. doi: 10.3390/metabo7020020.

3.

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP.

Pharmaceuticals (Basel). 2017 Feb 12;10(1). pii: E24. doi: 10.3390/ph10010024.

4.

Improving Ribosomal RNA Integrity in Surgically Resected Human Brain Tumor Biopsies.

Castells Domingo X, Ferrer-Font L, Davila M, Candiota AP, Simões RV, Fernández-Coello A, Gabarrós A, Boluda S, Barceló A, Ariño J, Arús C.

Biopreserv Biobank. 2016 Apr;14(2):156-64. doi: 10.1089/bio.2015.0086. Epub 2016 Feb 17.

PMID:
26886080
5.

Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.

Ferrer-Font L, Alcaraz E, Plana M, Candiota AP, Itarte E, Arús C.

Pathol Oncol Res. 2016 Jul;22(3):633-7. doi: 10.1007/s12253-015-9987-7. Epub 2015 Oct 14.

PMID:
26466942

Supplemental Content

Loading ...
Support Center